Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.73 CAD | -0.42% | -3.86% | +19.75% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.75% | 110M | |
+16.62% | 70.95B | |
+2.99% | 25.25B | |
+5.62% | 8.67B | |
+6.46% | 8.16B | |
-21.01% | 7.91B | |
+0.49% | 4.51B | |
+17.12% | 4.31B | |
-0.14% | 4.07B | |
-3.64% | 3.84B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Says Vascepa is Now Reimbursed by Ontario's Provincial Drug Plan